Halozyme Therapeutics Incorporated (HALO) 옵션

Have not had a chance to listen to CC. What did she say about new 1) Enhanze, 2) HVAI and 3) small volume autoinjector deals?

Earnings are out.
SAN DIEGO (AP) — SAN DIEGO (AP) — Halozyme Therapeutics Inc. (HALO) on Tuesday reported fourth-quarter profit of $137 million.

The San Diego-based company said it had net income of $1.06 per share. Earnings, adjusted for one-time gains and costs, came to $1.26 per share.

The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of $1.16 per share.

The biopharmaceutical company posted revenue of $298 million in the period, also surpassing Street forecasts. Six analysts surveyed by Zacks expected $284 million.

For the year, the company reported profit of $444.1 million, or $3.43 per share. Revenue was reported as $1.02 billion.

Halozyme Therapeutics expects full-year earnings in the range of $4.95 to $5.35 per share, with revenue in the range of $1.15 billion to $1.23 billion.

HALO, 10Q due 2/18

Elektrofi knows a lot about what Halozyme does and who they deal with and on what terms.

Chief Business Officer

Greg DeFilippis is the Chief Business Officer, responsible for Elektrofi’s go-to-market strategy, including revenue optimization, partnerships, and corporate development.

Greg is an experienced clinical and commercial leader with more than 20 years’ experience of pharmaceutical, biotech, and medical device industry experience. Having held C-suite and senior leadership positions he has a proven track record of successfully forming strategic partnerships, developing, launching and growing products with a focus on driving profitable revenue growth, building, and leading high-performing organizations.

Greg served as Chief Business Officer of Halozyme, leading the company’s licensing strategy for its technology and autoinjector device platforms as well as its strategic partnering strategy. Prior to Halozyme he served as Senior Vice President, Device Business and Alliances for Antares Pharma. Over the course of his career, Greg has helped partner, develop, and launch 17+ therapies including Xyosted®, Otrexup®, and the first generic AB rated EpiPen. He has held increasing roles of responsibilities for companies including Teva Pharmaceuticals, Barr Laboratories, Pliva, Actavis, and Alpharma.

Greg holds a Master of Business Administration in Finance from Fairleigh Dickinson University and a Bachelor of Science in Industrial and Systems Engineering from Virginia Tech. Greg is a certified Lean Six Sigma Master Black Belt.

Correction: pharmacokinetics not pharmacodynamics 

You are forgetting the extrcellular matrix. It makes absorption super slow via SC. So again if you want to have the same pharmacodynamics as IV, you need rhuph20. This is why you see the use of hyaluronidase all over Elektrofi's patent. You don't have to take my words for it. Look at their patents.

“Essentially, we take a drug substance (typically in liquid form) and convert it through a series of proprietary methodologies into an ensemble of very smooth and spherical microparticles,” Coffman explains. “Then we disperse those particles into an oily carrier medium that is eminently flowable and syringable, even at extremely high concentrations that are not otherwise accessible through conventional approaches to drug product formulation.”

Throughout the process, the protein molecule’s quality, shape, and size are preserved, and the concentration of injectable microparticle suspensions can exceed 600 mg/mL. In many cases, the concentration can be as much as five times that of standard formulations. Not only are Hypercon formulations capable of eliminating the need for infusions, they are also capable of reducing the frequency of injections by as much as half thanks to the concentrated dosages.
https://www.genengnews.com/topics/translational-medicine/protein-microparticles-turn-infusions-into-injectables/

This seems to contradict your theory, but I admit it is not totally clear.
In any event, Jannsen only paid $18 million upfront to have a go at it, with high backloaded payouts, which speaks to the speculative nature of the product as I read it.

If don't mind the concentrated biologic to sit in the subcutaneous space for a long time, then you won't need rhuph20. But if you are converting IV to SC and want similar pharmacodynamics, you definitely need rhuph20. 

I think the Hypercon technology allows the injection without the need for Enhanz, thereby being a direct competitor to HALO.

Good stuff. Yes, Elektrofi technology need's hyaluronidase. They (Elektrofi) merely concentrate theraputics/biologics. For the concentrated compund to be absorbed properly via SC route, you still need hyaluronidase. Let's hope they are using halo'a Enhanze and not the Korean's hyaluronidase. I suspect they are using halo's since they have been experimenting with hyaluronidase way before there a wanna be korean competitor.

I hope Helen doesn't buy Elektrofi before she has secured a HVAI partner first. We all saw how the market reacted with Evotec. She needs to show that there is innovation and continued EPS growth well into 2030's before pulling through trigger on an acquisition.

While hiding behind the couch, waiting for a reply, the breadcrumb investor fell asleep. Upon waking he saw messages up on the screen, one from the thread KiA and one from another poster. Nervously he read the posts, and was exuberant that they both left informative comments, and didn’t degrade or humiliate him. Still he was a little disappointed the KiA was to uppity to reply directly to original post. Even-though, the breadcrumb investor enthusiastically jumped out from behind the couch, did a little happy-dance, before jumping out the HALO-portal.

Unfortunately in his enthusiasm other valuable breadcrumbs, which he had wrapped in gold-foil, fell out go his pockets and burst open. Thus the HALO world learned what the inquisitive investor was really hiding, something he learned from following a breadcrumb left by a past poster. The breadcrumbs showed it is highly probable a deal will soon to be announced with Elektrofi, using its Hypercon technology to encapsulate Genentech’s rituximab, and HALO’s Enhance and AI technology for SC injection.

https://www.freepatentsonline.com/y2025/0026811.html

https://www.genengnews.com/topics/translational-medicine/protein-microparticles-turn-infusions-into-injectables/

https://www.elektrofi.com/news/elektrofi-janssen-biotech-enter-worldwide-collaboration

Amgen deal would be sweet! Thanks for sharing. And yes, I think Helen used to work for them.

However, isn't CARFILZOMIB already available as generic? May be Amgen wants to combine it with other biologics plus Enhanze. 

Interesting. Helen brought this drug to market in a previous lifetime.

Hiding his identity, the disgraced investor again sneaked thru the HALO-portal, crawled behind the couch, and tossed a breadcrumb onto the webpage for input from the thread know-it-all; cause the investor lacked the knowledge to determine whether the breadcrumb could lead to a deal with Amgen..........

29. The method of claim 28, wherein the hyaluronidase is PH20.

34. The method of any one of claims 1-33, wherein the carfilzomib is pegylated.

https://www.freepatentsonline.com/WO2025035020A2.html

I have been and remain a long but I must say, if Helen doesn't have a meaningful update on new partnerships (speciallly HVAI) next Tuesday, we might see a short term pull back.

... From MORGAN STANLEY:

"Halozyme has developed the first clinically demonstrated high volume auto-injector capable of delivering up to 10 mL rapidly in 30 seconds. This innovation combines Halozyme's expertise, auto-injector technology, and ENHANZE drug delivery technology to enable large volume subcutaneous injections that were previously not possible. The HVAI addresses a high unmet need, as there are no other devices that can rapidly deliver such high volumes subcutaneously."

Morgan Stanley assumes coverage of Halozyme at an Overweight rating and a price target of $67. 

Re Auto injectors, I post this link of JPM's analysis of VKTX first posted by WorstLuck on the Biotech Values Board. Seems Helen needs to get on the phone and get to work on this opportunity.
https://x.com/TomSilver39/status/1887297561264070838

... can't fight the fundamentals. Permabears have been swimming against a strong fundamentals current since we were in $teens, $20's, $30's, $40's and $50. Each time there has been a pull back, they claimed victory only to be proven wrong again and again. Can't go against growing earnings with profit margins offered at a PEG of 0.5 and forward PE of 11.

We need Helen to deliver an HVAI deal. It's been 2 years since she first promised it. We will easily be in $75-$95 range depending on the size of the deal. 

But even without one, we are headed to $60's. This is what permabears did not undestand when we they were forcasting doom and gloom in November. Anyone listening to them would have missed out on a 33% run we've had from low 40's.

....& THANK YOU HELEN !

THANK YOU!

Halozyme is tied for the No. 1 spot out of 730 stocks in the Medical-Biomed/Biotech group, which ranks No. 70 out of the 197 industry groups tracked by Investor's Business Daily. https://www.investors.com/stock-lists/sector-leaders/halozyme-stock-halo-biotech/

Sure am enjoying this "languishing" !

H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $70 from $68 and keeps a Buy rating on the shares. https://markets.businessinsider.com/news/stocks/halozyme-price-target-raised-to-70-from-68-at-h-c-wainwright-1034214389

Benchmark Co. analyst Robert Wasserman maintains Halozyme with a buy rating, and adjusts the target price from $60 to $75. https://news.futunn.com/en/post/52757517/benchmark-co-maintains-halozyme-therapeutics-halous-with-buy-rating-raises?level=1&data_ticket=1738679929267789

Royalties should not be affected. 

How will the new tariffs effect HALO?

Better to languish at this level than 42. Still needs some deals to prove out there thesis so don’t expect much until then.

... I must say, it is "languishing" quite well. Just like it "drifted" superbly after beating and raising immediately following quarterly results. LOL.

"Momentum traders"?! Not.

... and I might add how the share price is behaving 

Conversations.

Based on what?

This year is my guess.

So WHEN do people think we will see the first HVAI?

I hope its $20 but I say close to $10.
Around $7.50. About 15%.

How much do you all think the first HVAI will add to the share price? $10, $15, $20?

ditto!

Well said

You thought an article wasn't encouraging.
Biotech1 thought it was inconsequential.
Everyone is entitled to their opinion. If you can't handle
that yes you should leave.

Well as always sorry to bring news to this site.........the great know it all BI1 will always find fault.......which is why there is no reason to post the good stuff....

Gooooo Dr Torley....will be waitng for the new PR on a new client, using rhuph and an AI......as noted in several recent patent filings.......

Out of here.......

Inconsequential. The UK decision has to do with Herceptin SC and Mabthera SC. Back then Roche did not file RHUPH20 as an active ingredient early in the process. So the court is saying that they should have done so from the beginning of their filing. Since then everyone has learned their lessons. 

RHUPH20 is considered as active ingredient by the FDA and EU for pretty much all filings since Mabthera and Herceptin. Just look at the FDA package insert for Phego and Faspro and you will see RHUPH20 named as a separate active ingredient.

Potter Clarkson article yesterday wasn't that encouraging, IMO, FWIW.

Hmm. There is no way this board was created in 1970. Is that is Fred DOB?

Probably nothing.

Any news for this after hours spike ?

After Hours: Last | 6:44 PM EST
59.06
quote price arrow up+3.12 (+5.58%)
Volume
21,634

Thanks Minninv, the eMag was jsut general info, and did not expect a comment. Yes you are correct, never thought ATRS AIs were competitive, since the competition is just to large, and could under cut ATRS (Halozyme) costs. Always thought the best use of ATRS AIs was for developing internal AI combos, such as the one below. Was expecting HALO to finish up those combos in progress and develop many more, since HALO has the money, and ATRS never did have much money. But noooo, Dr Torley wanted to develop more AIs no one seems to want. Developing small niche market products is not what Dr Torley wants to do, expectations are to big.

https://www.empr.com/home/news/drugs-in-the-pipeline/hydrocortisone-rescue-pen-fast-tracked-for-adrenal-insufficiency/

https://www.freepatentsonline.com/12102643.html

100 percent agree with everything here. That’s exactly why I feel the stock is languishing. She totally missed the boat on the interview and that article is spot on. Need deals to change this.

... having said all this, these misunderstandings give the sophisticated investor who takes the time to look under the hood an advantage. Enjoy these bargain halo prices. Happy loading!

Helen, unfortunately, is not the best communicator. An example of this is her answer to the last question on her Bloomberg appearance today. When asked about the FDA rejection of amivantamab SC, she did not say that it was because of a standard pre-approval inspection at a manufacturing facility. Per J&J’s release, “The CRL is unrelated to the product formulation, or the efficacy and safety data submitted in the regulatory application, and the FDA has not requested any additional clinical studies.” Helen did not relay any of this
She also missed the opportunity to tout the innovative and groundbreaking HVAI technology with a brand new patent or mention the possibility of US Enhanze patent extension to 2029.
Halo is undervalued because investors are worried that if halo doesn’t get new partners (either HVAI or new coformulation-patent protected Enhanze deals) the earnings growth might slow down in the 2030’s.
She had an opportunity to address and reassure investors today and missed the chance.
We need her to communicate more clearly and know what points to get acrossed. Otherwise the general investor does not have the attention span to dig deep and learn the nuances of co-formulation patent which protect earnings well into 2030’s or new innovative platforms like HVAI. And this is why we end up with half-baked superficially researched articles like this one: (this guy didn’t even take the time to learn that the EU ENHANZE patent was already from 2024 to 2029.):
https://financial-engineering.net/halozyme-therapeutics-an-overlooked-bargain-new-stock-idea/